We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $980M
1-Year Est. Return 470.8%
This Fund
S&P 500
This Quarter Est. Return
+20.65%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$330M
AUM Growth
+$6.54M
Cap. Flow
+$45.9M
Cap. Flow %
13.92%
Top 10 Hldgs %
38.17%
Holding
104
New
22
Increased
33
Reduced
18
Closed
24

Top Buys

Rank Stock Value
1
MORF
Morphic Holding, Inc. Common Stock
MORF
+$17.8M
2
URGN icon
UroGen Pharma
URGN
+$8.17M
3
MRSN
Mersana Therapeutics
MRSN
+$7.61M
4
GOSS icon
Gossamer Bio
GOSS
+$7.06M
5
CBAY
Cymabay Therapeutics
CBAY
+$5.7M

Top Sells

Rank Stock Value
1
SDGR icon
Schrodinger
SDGR
+$10.3M
2
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$10.2M
3
AKRO
Akero Therapeutics
AKRO
+$9.78M
4
KRYS icon
Krystal Biotech
KRYS
+$5.78M
5
ETNB
89bio
ETNB
+$5.64M

Sector Composition

Rank Sector Weight
1 Healthcare 81.31%
2 Consumer Staples 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLNN icon
76
Clene
CLNN
$64M
$248K 0.08%
25,000
+12,500
+100% +$173K
SLRN
77
PUT
DELISTED
ACELYRIN
SLRN
$234K 0.07%
+23,000
New +$488K
SRRK icon
78
Scholar Rock
SRRK
$5.67B
$68.9K 0.02%
+9,711
New +$65.3K
RCKTW icon
79
Rocket Pharmaceuticals Warrant
RCKTW
$149K
$17.8K 0.01%
104,828
– –
ACRS icon
80
PUT
Aclaris Therapeutics
ACRS
$726M
$16.4K 0.01%
+2,400
New +$20.5K
ACRS icon
81
Aclaris Therapeutics
ACRS
$726M
– –
-219,229
Closed -$1.87M
ALLK
82
DELISTED
Allakos
ALLK
– –
-200,000
Closed -$872K
ANIP icon
83
ANI Pharmaceuticals
ANIP
$1.8B
– –
-54,041
Closed -$2.91M
BBIO icon
84
BridgeBio Pharma
BBIO
$15.7B
– –
-50,000
Closed -$860K
CLDX icon
85
Celldex Therapeutics
CLDX
$2.99B
– –
-10,000
Closed -$339K
CUE icon
86
Cue Biopharma
CUE
$113M
– –
-13,447
Closed -$1.47M
KYNB
87
CALL
Kyntra Bio
KYNB
$27.2M
– –
-4,000
Closed -$271K
GKOS icon
88
Glaukos
GKOS
$9.83B
– –
-1,000
Closed -$71.2K
GLUE icon
89
Monte Rosa Therapeutics
GLUE
$1.4B
– –
-31,156
Closed -$213K
IMTX icon
90
Immatics
IMTX
$1.18B
– –
-30,715
Closed -$354K
INCY icon
91
Incyte
INCY
$24.2B
– –
-34,110
Closed -$2.12M
JSPR icon
92
Jasper Therapeutics
JSPR
$21M
– –
-50,000
Closed -$685K
MLTX icon
93
MoonLake Immunotherapeutics
MLTX
$1.57B
– –
-200,000
Closed -$10.2M
NUVL
94
DELISTED
Nuvalent
NUVL
– –
-115,067
Closed -$4.85M
PHAT icon
95
Phathom Pharmaceuticals
PHAT
$708M
– –
-200,000
Closed -$2.86M
PHVS icon
96
Pharvaris
PHVS
$2.28B
– –
-200,000
Closed -$3.03M
PTGX icon
97
Protagonist Therapeutics
PTGX
$8.79B
– –
-25,000
Closed -$691K
VKTX icon
98
Viking Therapeutics
VKTX
$3.7B
– –
-258,595
Closed -$4.19M
VTYX
99
DELISTED
Ventyx Biosciences
VTYX
– –
-25,000
Closed -$820K
PVLA
100
Palvella Therapeutics
PVLA
$1.99B
– –
-12,017
Closed -$159K
1 2 3
4
5

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
GFP
Gryphon Financial Partners Columbus, Ohio $976M AUM 23.05% 1-Year Est. Return
ADIC
Abu Dhabi Investment Council Abu Dhabi, United Arab Emirates $975M AUM
PCM
Politan Capital Management New York $985M AUM 3.12% 1-Year Est. Return

Silverarc Capital Management's Q3 2023 Portfolio in Review

As of Q3 2023, Silverarc Capital Management held 104 positions worth $330M, up 2% from $323M the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Silverarc Capital Management deployed $45.9M of net new capital in Q3 2023, opening 22 new positions and adding to 33 existing holdings. Its largest new stake was UroGen Pharma: 508,883 shares worth $7.13M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 92% a quarter earlier, followed by Consumer Staples.

On the sell side, the largest reduction was Schrodinger, an estimated $10.3M trimmed.

  • Silverarc Capital Management's largest Q3 2023 buy was UroGen Pharma: 508,883 shares worth $7.13M.
  • Silverarc Capital Management added most to Morphic Holding, Inc. Common Stock in Q3 2023, an estimated $17.8M increase.
  • Silverarc Capital Management's biggest Q3 2023 reduction was Schrodinger, cutting an estimated $10.3M.
  • Silverarc Capital Management fully exited MoonLake Immunotherapeutics in Q3 2023, selling an estimated $10.2M.
  • Silverarc Capital Management's ten largest holdings make up 38% of its $330M portfolio in Q3 2023.
  • Silverarc Capital Management opened 22 new positions and closed 24 in Q3 2023.
  • Silverarc Capital Management's portfolio value rose 2% quarter-over-quarter to $330M.

Based on Silverarc Capital Management's 13F filing for Q3 2023, filed 13 Nov 2023.